Association between insulin resistance and prostate volume: A 4‐year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial
BJUI Compass · 2025-09 · 6 (9)
DOI: 10.1002/bco2.70085 ↗At a glance
Journal article in BJUI Compass, published online on 2025-09-14. Written by James P Daniels and 6 co-authors. Institution: Department of Urology University of Louisville Louisville Kentucky USA. Cited 2 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (original language)
Objectives
Most, but not all studies, suggest insulin resistance is associated with benign prostatic hyperplasia, but its impact on prostate volume (PV) changes over time remains unclear. We examined whether higher insulin resistance, measured by Homeostatic Model Assessment of Insulin Resistance (HOMA‐IR), is associated with larger PV and greater prostate growth over a 4‐year period. Materials and Methods We analysed data from the 4‐year, randomized, double‐blind, placebo‐controlled REDUCE trial testing whether dutasteride could prevent prostate cancer. Patients underwent transrectal ultrasound measuring PV at baseline, year 2 and year 4. We calculated HOMA‐IR from baseline fasting glucose and insulin, then stratified patients into quartiles within each arm (placebo vs. dutasteride). Using multivariable models, we estimated PV changes over time. We conducted a sensitivity analysis excluding patients with diabetes.
Results
Higher HOMA‐IR quartiles were associated with larger PV at baseline, year 2 and year 4 in both placebo and dutasteride arms (all p < 0.001), though absolute differences were modest. PV increased in the placebo arm over 4 years, whereas it decreased in the dutasteride arm. However, there was no significant association between HOMA‐IR and PV change in either arm. Results remained unchanged after excluding patients with diabetes.
Conclusion
Patients with higher HOMA‐IR had modestly larger PVs at baseline, year 2 and year 4, but insulin resistance was unrelated to PV change over four years. These findings suggest that insulin resistance may be a modifiable risk factor contributing to benign prostatic enlargement, though further research is needed to determine its clinical relevance.
Subjects
Author keywords
Authors and institutions
- Department of Urology University of Louisville Louisville Kentucky USA.
- Department of Urology Cedars-Sinai Medical Center Los Angeles CA USA.
- Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center California Los Angeles USA.
- Clinical and Translational Science Institute Cedars-Sinai Medical Center California Los Angeles USA.
- School of Medicine, Tsinghua Medicine Tsinghua University Beijing China.
- A.T. Still University College of Osteopathic Medicine Kirskville MO USA.
ORCID profiles: Alexander Hernández-Tirado, Stephen J Freedland
Funding
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Cite
APA
Daniels, J. P., Hernández-Tirado, A., Mirocha, J., Zheng, R., Palmer, J., Moreira, D., & Freedland, S. J. (2025). Association between insulin resistance and prostate volume: A 4‐year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. BJUI Compass, 6(9). https://doi.org/10.1002/bco2.70085
Vancouver
Daniels JP, Hernández-Tirado A, Mirocha J, Zheng R, Palmer J, Moreira D, et al. Association between insulin resistance and prostate volume: A 4‐year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. BJUI Compass. 2025;6(9). doi:10.1002/bco2.70085
BibTeX
@article{Daniels2025,
author = {Daniels, James P and Hernández-Tirado, Alexander and Mirocha, James and Zheng, Renning and Palmer, Jordan and Moreira, Daniel and Freedland, Stephen J},
title = {Association between insulin resistance and prostate volume: A 4‐year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial},
journal = {BJUI Compass},
year = {2025},
volume = {6},
number = {9},
doi = {10.1002/bco2.70085}
}
EUVIMED